Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694483 | 1.00 | MCHR1 (0.57) | MCHR1CCR1KMT2AMAPTALDH1A1 | |
| SCHEMBL13739153 | 0.82 | MCHR1 (0.60) | MCHR1CCR1KMT2AMAPTALDH1A1 | |
| SCHEMBL27947067 | 0.82 | NCF1 (0.48) | MCHR1CCR1MAPTALDH1A1HPGD | |
| SCHEMBL16107146 | 0.80 | MCHR1 (0.54) | MCHR1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL12066587 | 0.79 | KMT2A (0.62) | MCHR1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL7513556 | 0.79 | KMT2A (0.62) | MCHR1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL28613689 | 0.79 | MCHR1 (0.63) | MCHR1CCR1KMT2AMAPTKDM4E | |
| SCHEMBL7513553 | 0.79 | KMT2A (0.62) | MCHR1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL763980 | 0.79 | CCR1 (0.47) | MCHR1CCR1KMT2AMAPTALDH1A1 | |
| SCHEMBL13739010 | 0.78 | MCHR1 (0.66) | MCHR1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529141-A | Preparation method of quinoline amino binuclear metal titanium zirconium hafnium catalyst and application of catalyst in olefin polymerization | 青岛科技大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20240010913-A1 | RED FLUORESCENT SENSOR COMPOUNDS FOR THE DETECTION OF METAL IONS | FEMTONICS KFT. (HU) | 2024-01-11 | — | — | US | disclosed |
| WO-2022118054-A1 | RED FLUORESCENT SENSOR COMPOUNDS FOR THE DETECTION OF METAL IONS | FEMTONICS KFT. (HU) | 2022-06-09 | — | — | WO | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021008588-A1 | CLASS OF PYRIMIDINE QUINOLINE DERIVATIVES AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 广州新民培林医药科技有限公司 | 2021-01-21 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1496897-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050239815-A1 | Tyrosine kinase inhibitors | KIM ANNETTE J | 2005-10-27 | — | — | US | disclosed |
| EP-1496897-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086395-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-3953428-A | ANTIBACTERIAL | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | MCHR1 417/4885CCR1 2228/4885KMT2A 687/4885 |
| US-20050239815-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | MCHR1 417/4885CCR1 2228/4885KMT2A 687/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | MCHR1 4238/4885CCR1 205/4885KMT2A 415/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | MCHR1 3842/4885CCR1 128/4885KMT2A 231/4885 |
| US-20240010913-A1 | RED FLUORESCENT SENSOR COMPOUNDS FOR THE DETECTION OF METAL IONS | SLC30A6, SLC30A7, SLC39A14 | MCHR1 909/4885CCR1 3740/4885KMT2A 3909/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | MCHR1 3827/4885CCR1 3552/4885KMT2A 1967/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | MCHR1 4735/4885CCR1 1459/4885KMT2A 134/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | MCHR1 4221/4885CCR1 2856/4885KMT2A 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.